Q1 2019 RESULTS

FINANCIAL PERFORMANCE

GAAP NET REVENUE $3.6B

PERFORMANCE NET INCOME PER SHARE 1 $3.79

GAAP Loss Per Share $7.25

Q1 HIGHLIGHTS

CORE BUSINESS GREW 4.4% ON STRENGTH IN FACIAL AESTHETICS AND CENTRAL NERVOUS SYSTEM 1, 2

QUARTERLY CASH DIVIDEND RAISED TO $0.74 PER SHARE

R&D PIPELINE ADVANCED IN KEY LATE STAGE PROGRAMS INCLUDING UBROGEPANT ABICIPAR BIMATOPROST SR

GAAP REVENUE DRIVEN BY GROWTH IN TOP PROMOTED PRODUCTS:

1 Please refer to the GAAP to non-GAAP tables in May 7, 2019 Press Release on Allergan.com for a reconciliation of our non-GAAP results.
2 Core Business = Promoted Brands & Brands with Ongoing Exclusivity + Other Product Revenue + Other Revenue. Growth percentage vs. Q1 2018, excluding FX. Please refer to Table 13 in May 7, 2019 Investor Deck on Allergan.com for details on products included.